Article
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Cancer letters - 28 Jan 2017
Wu Fei, Dai Xiangpeng, Gan Wenjian, Wan Lixin, Li Min, Mitsiades Nicholas, Wei Wenyi, Ding Qiang, Zhang Jinfang
Abstract excerpt
Recent studies revealed that mutations in SPOP (Speckle-type POZ protein) occur in up to 15% of patients with prostate cancer. However, the physiological role of SPOP in regulating prostate tumorigenesis remains elusive. Here, we identified the Cdc20 oncoprotein as a novel ubiquitin substrate of SPOP. As such, pharmacological inhibition of Cullin-based E3 ligases by MLN4924 could stabilize endogenous Cdc20 in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.